China NT Pharma Group Co (HKSE:01011) Research & Development: HK$0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01011 China NT Pharma Group Co Ltd HKSE:01011
1 GF Score
Price HK$0.42
! 4 Warning Signs
View Full Analysis

What is China NT Pharma Group Co Research & Development?

China NT Pharma Group Co HKSE:01011 -6.67% 1 Research & Development is HK$0.00 Mil as of Dec. 2025. GuruFocus rates HKSE:01011 with a GF Score™ of 1/100. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. China NT Pharma Group Co's Research & Development for the six months ended in Dec. 2025 was HK$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.00 Mil.

China NT Pharma Group Co  (HKSE:01011) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

China NT Pharma Group Co Research & Development Related Terms

China NT Pharma Group Co Research & Development Historical Data

* Premium members only.

The historical data trend for China NT Pharma Group Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China NT Pharma Group Co Research & Development Chart

China NT Pharma Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

China NT Pharma Group Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:01011
1GF Score
China NT Pharma Group Co Ltd HKSE:01011
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China NT Pharma Group Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$0.00 Mil mean?
China NT Pharma Group Co (HKSE:01011) has a Research & Development of HK$0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on China NT Pharma Group Co and its competitors.
Is China NT Pharma Group Co's Research & Development too high?
China NT Pharma Group Co's current Research & Development is HK$0.00 Mil. Overall, China NT Pharma Group Co has a GF Score™ of 1/100, reflecting its overall financial health beyond just this single metric.
How does China NT Pharma Group Co's Research & Development compare to ZTS?
China NT Pharma Group Co's Research & Development of HK$0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on China NT Pharma Group Co and its competitors. China NT Pharma Group Co's current Research & Development is HK$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China NT Pharma Group Co stock overvalued right now?
China NT Pharma Group Co (HKSE:01011) has a current Research & Development of HK$0.00 Mil. The current Research & Development is HK$0.00 Mil. China NT Pharma Group Co's overall GF Score™ is 1/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For China NT Pharma Group Co (HKSE:01011), the current Research & Development is HK$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

China NT Pharma Group Co Business Description

Address 168-200 Connaught Road, Unit 2102, 21st Floor, West Tower, Shun Tak Centre, Central, Hong Kong, HKG
China NT Pharma Group Co Ltd is a technology-based pharmaceutical company. It is engaged in research and development, production, and sale of private-label drugs, as well as the provision of pharmaceutical marketing and promotion services in China. It focused on the research, development, production, and sales of orthopedic, psychiatric, and oncology drugs. The Group's operations are regarded as having two operating and reportable segments, namely Agency Services and Healthcare Related Services. The company generates maximum of its revenue from Healthcare Related Services.
1GF Score

Get the complete analysis for HKSE:01011

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.42
Price